Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

Abstract: The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non‐alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti‐NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti‐asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver‐related metabolic diseases.

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast ; volume:15 ; number:1 ; year:2020 ; pages:50-67 ; extent:18
ChemMedChem ; 15, Heft 1 (2020), 50-67 (gesamt 18)

Urheber
Schierle, Simone
Helmstädter, Moritz
Schmidt, Jurema
Hartmann, Markus
Horz, Maximiliane
Kaiser, Astrid
Weizel, Lilia
Heitel, Pascal
Proschak, Anna
Hernandez‐Olmos, Victor
Proschak, Ewgenij
Merk, Daniel

DOI
10.1002/cmdc.201900576
URN
urn:nbn:de:101:1-2022062513272386937074
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:37 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.

Beteiligte

Ähnliche Objekte (12)